Drug interactions between chemotherapeutic regimens and antiepileptics

Yap, Kevin Yi-Lwern; Chui, Wai Keung; Chan, Alexandre

doi:10.1016/j.clinthera.2008.08.011

Cited by 144 publications

(95 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chemosensitivity of the primary tumor is the major determinant of the response to systemic treatment for brain metastases (92,95), although asymptomatic brain metastases may have lower responses than systemic tumors to systemic chemotherapy (82). Dexamethasone and enzyme-inducing anti-epileptic drugs (EIAEDs) can induce cytochrome p450 3A isoenzymes, including CYP3A4, which metabolizes chemotherapeutic agents (96,97) including paclitaxel, irinotecan, vinorelbine, cyclophosphamide, doxorubicin, etoposide, ifosfamide, teniposide, erlotinib, and gefitinib. Therefore, co-administration of EIAEDs or dexamethasone may increase the metabolism of chemotherapeutic agents, lower plasma concentrations, and reduce efficacy.…”

Section: Discussionmentioning

confidence: 99%

Medical Management of Brain Metastases from Lung Cancer

Yamanaka¹

2011

Brain Tumors - Current and Emerging Therapeutic Strategies

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Medical Management of Brain Metastases from Lung Cancer

Yamanaka¹

2011

Brain Tumors - Current and Emerging Therapeutic Strategies

View full text Add to dashboard Cite

“…Dexamethasone and enzyme-inducing anti-epileptic drugs (EIAEDs) can induce cytochrome p450 3A isoenzymes, including CYP3A4, which metabolizes chemotherapeutic agents (86,87) including paclitaxel, irinotecan, vinorelbine, cyclophosphamide, doxorubicin, etoposide, ifosfamide, teniposide, erlotinib and gefitinib. Therefore, co-administration of EIAEDs or dexamethasone may increase the metabolism of chemotherapeutic agents, lower plasma concentrations, and reduce efficacy.…”

Section: Discussionmentioning

confidence: 99%

Medical management of brain metastases from lung cancer (Review)

Yamanaka¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Brain metastases are a frequent complication in patients with lung cancer and a significant cause of morbidity and mortality. The prognosis of these patients is poor. Medical therapies for brain metastases are neither wellstudied nor established. This review analyzes the impact of medical treatment on survival by reviewing recent articles of the management of brain metastases from lung cancer patients. Chemotherapy for brain metastases from lung cancer is effective for both small cell and non-small cell lung cancer. Since brain metastases are part of systemic progression, chemotherapy should always be considered for the therapeutic management of brain metastases. Available data and response rates in lung cancer patients indicated that medical treatment for the management of brain metastases should be part of a multimodality treatment.

show abstract

“…However, the increase in the use of combination therapies in cancer patients poses them to high risks of manifesting drug-drug interactions (DDIs) [6,7]. This is because anticancer drugs (ACDs) not only have complex pharmacological profiles, but also narrow therapeutic indices and steep dose-toxicity curves.…”

Section: Introductionmentioning

confidence: 99%

“…Clinicians must be vigilant when prescribing other concomitant medications with ACDs so as to prevent unwanted toxicities and inadequate drug exposures due to DDIs. Pharmacokinetic and/or pharmacodynamic interactions can lead to clinically significant toxicities or therapeutic failures [6]. Thus, it is essential that they know the magnitude of the DDIs so as to better manage their patients' drug therapies.…”

Section: Introductionmentioning

confidence: 99%